Today: 22 May 2026
Lumentum stock jumps 7% as AI optics rally resumes, putting focus back on convertible-note risk

Lumentum stock jumps 7% as AI optics rally resumes, putting focus back on convertible-note risk

New York, Feb 9, 2026, 11:03 EST — Regular session underway.

  • Lumentum was up roughly 7% in late-morning action, building on last week’s rally.
  • Focus among investors stayed on the company’s bullish forecast, driven by AI data-center optics demand.
  • A recent filing pointed to risks if convertible debt is cleared for early conversion.

Lumentum Holdings Inc. jumped over 7% on Monday, extending last week’s surge for the Nasdaq-listed AI optics stock.

Lumentum plays a pivotal role in the AI infrastructure, handling the optical gear responsible for moving data inside and between data centers. Its shares now act as something of a sentiment gauge for traders betting on the AI story’s next leg.

Another thread running through investor conversations: as shares climb, convertible notes become simpler to flip, which can quickly put pressure on a company’s liquidity numbers if big holders decide to act.

Lumentum jumped 7.3% to $592.50 in late-morning action after reaching $598.89 earlier. Coherent, another optics name, climbed 6.4%. The Invesco QQQ, packed with tech stocks, was up around 0.5%.

Last week, the company posted fiscal Q2 revenue of $665.5 million, with non-GAAP earnings landing at $1.67 per share. For the third quarter, the outlook calls for revenue somewhere between $780 million and $830 million, and non-GAAP EPS in a $2.15 to $2.35 range. CEO Michael Hurlston pointed to surging demand for optical circuit switches, pushing backlog “well beyond $400 million.” He also mentioned a fresh “multi-hundred-million-dollar” co-packaged optics order, set for delivery in the first half of calendar 2027. investor.lumentum.com

Lumentum disclosed in its latest quarterly filing that its stock traded high enough during the December period to trigger conversion rights for its convertible notes—an option holders can exercise if the shares hit certain price levels. The company said it’s on the hook to pay out the principal in cash. It flagged a risk: if a large number of noteholders choose to convert at once, liquidity could take a hit, and the conversion feature “raises a substantial doubt” about Lumentum’s ability to stay afloat. SEC

Right now, traders are eyeing the stock’s rally to see if it actually brings in conversions and cash, or if it ends up as nothing more than an accounting overhang. They’re also tracking whether Lumentum manages to clear out its switch backlog with deliveries—without sacrificing margins along the way.

The risk is clear enough: should the AI-fueled capex cycle lose steam or clients delay deployments, orders could fall off—and these volatile optics stocks tend to tumble quickly. On the flip side, if conversions pick up speed, Lumentum might feel forced to tap financing options it would ideally prefer to leave on the table.

Tech stocks facing rate pressure will get their next reality check this week: U.S. January jobs numbers hit Feb. 11, January CPI lands Feb. 13. Both drop at 8:30 a.m. Eastern.

Stock Market Today

  • NYSE's Martin Questions Nasdaq Rules Attracting SpaceX IPO
    May 22, 2026, 9:22 AM EDT. Lynn Martin, President of the New York Stock Exchange (NYSE), criticized some of the Nasdaq's listing rules used to attract SpaceX's public offering as "questionable." Speaking on Bloomberg Surveillance, Martin emphasized that market integrity should not be compromised for competitive gains between stock exchanges. She noted 2023 has been a strong year for initial public offerings (IPOs) across sectors and affirmed the NYSE's commitment to bringing more companies public. Martin's remarks highlight ongoing debates over regulatory standards and competitive practices in the IPO market.

Latest articles

Akari Therapeutics Stock Is Soaring Again — The KRAS Cancer Data Behind the Move

Akari Therapeutics Stock Is Soaring Again — The KRAS Cancer Data Behind the Move

22 May 2026
New York, May 22, 2026, 09:08 EDT Akari Therapeutics shares were indicated sharply higher before the Nasdaq open on Friday, after the oncology biotech said its lead cancer drug candidate showed positive preclinical activity in KRAS-mutated pancreatic cancer models and priced a $5.5 million private placement. The stock closed Thursday at $5.14, up 49.85%, and was quoted at $10.15 in premarket trading at 8:39 a.m. EDT, according to StockAnalysis. The move matters because Akari is still a preclinical company, not a revenue-producing drugmaker. Its latest data give investors a fresh reason to look at AKTX-101, while the financing gives the
BMO Lands Buy Rating Ahead of Earnings But Targets Raise Questions

BMO Lands Buy Rating Ahead of Earnings But Targets Raise Questions

22 May 2026
Canaccord Genuity reaffirmed a Buy rating on Bank of Montreal ahead of its May 27 earnings report. BMO shares closed May 21 at C$220.06, near a 52-week high and up 23.5% year-to-date. The bank recently agreed to sell C$14.5 billion in loan and lease assets to Stonepeak, expecting a CET1 ratio boost but a C$900 million after-tax charge. Analyst consensus remains mixed, with most holding or selling.
Atmos Energy’s run in Texas faces new Wall Street target cut

Atmos Energy’s run in Texas faces new Wall Street target cut

22 May 2026
Morgan Stanley lowered its Atmos Energy price target to $183 from $195, maintaining an Equalweight rating. The move follows Atmos’ recent increase in its 2026 earnings outlook and annual dividend. Atmos shares closed at $177.46 on Thursday. Texas remains central to Atmos’ growth and regulatory strategy, with 65% of its rate base in the state.
Plug Power stock back in play as Feb. 17 share-vote redo nears
Previous Story

Plug Power stock back in play as Feb. 17 share-vote redo nears

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution
Next Story

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution

Go toTop